What is Leerink Partnrs' Forecast for Zura Bio Q1 Earnings?

Key Points

• Leerink Partners estimates Zura Bio will report earnings of ($0.19) per share for Q1 2026, with a full-year earnings estimate of ($0.65) per share.
• Multiple analysts have given Zura Bio a consensus rating of "Buy" along with a target price of $14.17, although Oppenheimer has lowered their target from $17.00 to $16.00.
• Zura Bio's stock recently opened at $1.66, with a significant market cap of $113.51 million and a twelve-month high of $5.07.

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Zura Bio in a research report issued to clients and investors on Thursday, August 14th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings of ($0.19) per share for the quarter. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio's Q2 2026 earnings at ($0.19) EPS.

ZURA has been the topic of a number of other research reports. Chardan Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Zura Bio in a report on Friday, August 15th. Oppenheimer reduced their target price on Zura Bio from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday, August 15th. Finally, HC Wainwright reduced their target price on Zura Bio from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $14.00.

Zura Bio Stock Performance

Zura Bio stock traded up $0.0290 during midday trading on Monday, reaching $2.0190. The stock had a trading volume of 301,357 shares, compared to its average volume of 515,752. Zura Bio has a twelve month low of $0.97 and a twelve month high of $5.07. The stock has a market capitalization of $138.05 million, a PE ratio of -2.89 and a beta of -0.06. The stock's 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.32.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Advisers LP acquired a new position in shares of Zura Bio during the fourth quarter worth about $32,000. Savant Capital LLC lifted its stake in shares of Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company's stock worth $34,000 after purchasing an additional 21,249 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the fourth quarter worth about $35,000. XTX Topco Ltd acquired a new position in shares of Zura Bio in the fourth quarter worth about $44,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock worth $58,000 after acquiring an additional 9,379 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.